Condition: Anorexia Nervosa · Bulimia Nervosa · Binge-Eating Disorder · Sponsor: University of North Carolina, Chapel Hill
The overarching intention of the Eating Disorder Genetics Initiative 2 (EDGI2) is to increase sample size, diversity, and eating disorder phenotypes. The investigators are enrolling 20,000 new participants with anorexia nervosa (AN), bulimia nervosa (BN), binge-eating disorder (BED), avoidant/restrictive food intake disorder (ARFID), and controls in the US, Mexico, Australia, New Zealand, Sweden, and Denmark. A primary study goal is to enroll at least 30% of participants from underrepresented groups. Participants are asked to complete a series of questionnaires and submit a saliva sample for genotyping. The goal is to better understand eating disorders and how they relate to each other so that better treatments can be developed.
This description comes directly from the study's public registry record.
Laura M Thornton, PhD · 804-690-3079 · laura_thornton@med.unc.edu
Casey MacDermod, BA · 984-974-3798 · edgi2@unc.edu
Always discuss trial participation with your own doctor first.
| University of North Carolina at Chapel Hill | Chapel Hill, North Carolina, United States | Recruiting |
| QIMR Berghofer | Brisbane, Queensland, Australia | Recruiting |
| Comenzar de Nuevo | Monterrey, Mexico | Recruiting |
| University of Otago | Christchurch, Canterbury, New Zealand | Recruiting |
| Karolinska Institutet | Stockholm, Sweden | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06594913